Published in

Elsevier, The Lancet, 2023

DOI: 10.1016/s0140-6736(23)02408-x

Links

Tools

Export citation

Search in Google Scholar

Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial

Journal article published in 2023 by Katherine R. Tuttle, Sibylle J. Hauske, Maria Eugenia Canziani, Maria Luiza Caramori, David Cherney, Lisa Cronin, Hiddo J. L. Heerspink, Christian Hugo, Masaomi Nangaku, Ricardo Correa Rotter, Arnold Silva, Shimoli V. Shah, Zhichao Sun, Dorothea Urbach, Dick de Zeeuw and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO